This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As the pharmaceutical industry continues to evolve, drugdevelopers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinicalresearch business of Thermo Fisher Scientific conducted its third global survey of 150 drugdevelopers to capture a comprehensive view of these evolving trends.
As a result, drugdevelopers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. Ready to learn more about how to leverage AI and machine learning to maximize your clinical trial efficiency? Get in touch.
As the clinical trial landscape evolves, drugdevelopers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.
Distinguishing the Roles of Preclinical vs. Clinical CROs in ClinicalResearch Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drugdevelopment pipeline.
By: Sarah Bly and Aman Khera, Regulatory Science and Innovation The journey of bringing a new therapeutic agent from the laboratory to the marketplace is fraught with challenges, not least of which is navigating the complexities of regulatory feedback, which do not always converge but can diverge.
1 With this growth comes increased demands for laboratory services at all steps across the development process. Access to a laboratory partner that already possesses the equipment, knowledge and personnel can save time and money. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.
Laboratories Clear coordination for timely delivery of collection kits ensures there are no on-site delays once the allocated slot has been assigned and the patient’s journey has begun.
However, clinicalresearch around Fragile X is considerably robust, making the possibility of clinical trial participation a potential motivation for parents to choose to undergo genetic testing for their children. These datasets can help find providers and patients based on genetic information.
As a result, sponsors must decide whether to leverage a CRO partner even earlier in their drugdevelopment timelines to ensure proper planning for these constraints. How a CRO Accelerates ClinicalDevelopmentClinical trials are becoming increasingly complex as the industry evolves.
In clinicalresearch, the role of drug packaging systems cannot be overlooked. Industry guidelines require biopharmaceutical and biotechnology companies to test their pharmaceutical packaging systems, as the systems often experience prolonged and intimate contact with drug products, drug substances and intermediates.
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity. About QuartzBio QuartzBio helps overcome the data chaos inherent in modern drugdevelopment.
billion in 2023 attributable to its laboratory products and biopharma services segment (53.8% By type of service, clinicalresearch services accounted for the lion’s share of the North American CRO services market, followed by early-phase development services, laboratory services, and consulting services.
A good central lab will help reduce the costs and accelerate the timeline of a sponsor’s drugdevelopment program. A laboratory services partner that provides globally standardized clinical testing, centralized data visibility and a robust drugdevelopment database solution will help drive clinical trial success.
Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs pmjackson Tue, 04/16/2024 - 19:04 The gene therapy landscape continues to accelerate in preclinical and clinicalresearch, with programs constantly in development for targeted, personalized medicines.
Contract research organizations (CROs) are an integral partner of the drugdevelopment process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinical trials are actually managed by these organizations?
Clinicalresearch requires vast talent across a variety of roles and specialties, as well as across global locations. In this complex environment, functional service partnership (FSP) models have become a solution of choice for pharmaceutical and biotech companies navigating the challenges of clinicaldevelopment.
Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinicalresearch and development at companies across Europe and the US. Prior to VHsquared, Suhail was Senior Vice President and Head of Development and Medical Affairs for Shionogi in Europe.
Preclarus dashboards deliver unprecedented reporting scope that exceeds functional-based study reporting and integrates data collected from three main areas — the laboratory, the operations team and the clinical trial site.
The pharmaceutical and biotechnological landscape is constantly evolving and a key partner within the drugdevelopment process is contract research organizations (CROs) , who are at the forefront with sponsors to drive innovation in clinicalresearch.
Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow. In June 2023, the U.S.
Conclusive Evidence from Rigorous Clinical Trials Nine months later, results from the randomized, controlled trials of Veklury involving thousands of patients have been published in peer-reviewed journals, conclusively demonstrating the clinical benefits of treatment with Veklury.
Adverse reactions.
Representatives on both sides of the aisle took full advantage of their floor time to probe FDA leadership on its spending, performance and specific regulatory policies – including its recent LaboratoryDeveloped Test final rule. If you don’t have the staff to do this, how are you going to have the staff to do that?”
Moderna’s partner PPD (Nasdaq: PPD), a leading global contract research organization providing comprehensive, integrated drugdevelopment, laboratory and lifecycle management services, has also been essential to the successful execution of the COVE study. at large.
Moderna’s partner PPD (Nasdaq: PPD), a leading global contract research organization providing comprehensive, integrated drugdevelopment, laboratory and lifecycle management services, has also been essential to the successful execution of the COVE study. at large.
By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drugdevelopment A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Read AgencyIQ analysis here for a detailed discussion of these issues. ].
Interestingly, the agency noted that this is still the case when a sponsor adds “ancillary protocol-specific activities,” such as a questionnaire unique to the study that would not otherwise be captured in the course of medical care or supplementing a registry’s data collection with a specific laboratory test.
Title Type Comments Close Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief Guidance November 1 Post-Warning Letter Meetings Under GDUFA Guidance November 6 In-Home (..)
As 2022 comes to a close, we’re reflecting on the past 12 months as a transformative year for the drugdevelopment industry — one that foreshadows both change and opportunity in biopharma and biotech clinical trials in 2023. Six Predictions for the DrugDevelopment Industry in 2023 1.
Examples of these strategies include: Sustained community engagement; Providing cultural competency and proficiency training for investigators and research staff; Improving study participant awareness and knowledge of the clinical study (e.g., providing language assistance); Reducing participant burden (e.g.,
Date Group Event Notable FDA Speakers February 28 TransCelerate Rapid RWD Analyses to Support Safety Signal Assessments February 28 White House Rare Disease Forum Julie Tierney March 1 Foundation Fighting Blindness PFDD Meeting on Dry Age-Related Macular Degeneration (Dry AMD) March 4 America’s Blood Centers 2024 Annual Meeting Peter Marks March (..)
Title Type Comments Close Digital Health Technologies for Detecting Prediabetes and Undiagnosed Type 2 Diabetes January 31 Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement Meeting February 12 Advisory Committee; Genetic Metabolic Diseases Advisory Committee; Establishment Notice February 12 Advanced Manufacturing (..)
See AgencyIQ’s analysis for more detailed history of FDA’s policy and guidance on diversity in research studies ]. In April 2022, the FDA issued a draft guidance document on diversity in clinicalresearch programs. Read AgencyIQ’s extensive analysis of the draft guidance here.]
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content